

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2017/06/30	2016/12/31	2016/06/30
Balance Sheet			
Current assets			
Total cash and cash equivalents	445,681	309,771	406,372
Total Current investments in debt instrument without active market	215,553	455,399	510,850
Accounts receivable, net	31,236	23,328	9,232
Accounts receivable due from related parties, net	14,037	24,472	0
Other receivables, net	3,527	2,838	2,746
Total current tax assets	2,064	1,907	2,386
Total inventories	59,368	50,395	54,222
Total prepayments	23,356	19,989	45,467
Total other current assets	5,718	48,402	19,287
Total current assets	800,540	936,501	1,050,562
Non-current assets			
Non-current financial assets at cost, net	87,000	20,000	0
Total Non-current investments in debt instrument without active market	0	30,000	30,000
Total property, plant and equipment	359,285	315,000	274,969
Total intangible assets	2,225	2,342	1,100
Deferred tax assets	38,820	39,599	39,540
Total other non-current assets	25,267	45,906	57,111
Total non-current assets	512,597	452,847	402,720
Total assets	1,313,137	1,389,348	1,453,282
Current liabilities			
Total accounts payable	23,587	22,069	46,249
Total other payables	41,405	42,658	39,786
Other payables to related parties	0	6	0
Total other current liabilities	13,891	5,728	14,152
Total current liabilities	78,883	70,461	100,187
Non-current liabilities			
Total deferred tax liabilities	0	473	362
Total other non-current liabilities	2,241	2,271	1,714
Total non-current liabilities	2,241	2,744	2,076
Total liabilities	81,124	73,205	102,263
Share capital			
Ordinary share	1,120,885	1,120,005	1,118,180
Advance receipts for share capital	599	807	2,349
Total share capital	1,121,484	1,120,812	1,120,529
Capital surplus			
Total capital surplus, additional paid-in capital	265,798	621,104	618,481
Capital surplus, treasury share transactions	2,812	2,812	2,812
Capital surplus, employee share options	25,180	15,695	7,070
Total capital surplus	293,790	639,611	628,363
Retained earnings			
Total unappropriated retained earnings (accumulated deficit)	-95,650	-356,669	-310,262
Total retained earnings	-95,650	-356,669	-310,262
Other equity interest			
Total revaluation surplus	0	0	0
Total other equity, others	0	0	0
Total other equity interest	0	0	0
Treasury shares	-87,611	-87,611	-87,611
Equity attributable to former owner of business combination under common control	0	0	0
Equity attributable to non-controlling interest before business combination under common control	0	0	0
Total equity	1,232,013	1,316,143	1,351,019
Total liabilities and equity	1,313,137	1,389,348	1,453,282
Number of share capital awaiting retirement	0	0	0
Equivalent issue shares of advance receipts for ordinary share	29,500	44,000	120,500
Number of shares in entity held by entity and by its subsidiaries	2,200,000	2,200,000	2,200,000

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2017/2nd	2016/2nd	2017/01/01To2017/06/30	2016/01/01To2016/06/30
Income Statement				
Total operating revenue	74,024	30,060	99,258	40,029
Total operating costs	44,195	39,351	84,828	70,008
Gross profit (loss) from operations	29,829	-9,291	14,430	-29,979
Gross profit (loss) from operations	29,829	-9,291	14,430	-29,979
Operating expenses				
Total selling expenses	5,105	2,375	7,052	4,460
Total administrative expenses	10,495	7,733	21,518	14,811
Total research and development expenses	44,936	47,910	85,042	88,986
Total operating expenses	60,536	58,018	113,612	108,257
Net operating income (loss)	-30,707	-67,309	-99,182	-138,236
Non-operating income and expenses				
Total other income	7,539	14,675	13,829	28,046
Other gains and losses, net	482	101	-9,991	-2,178
Total non-operating income and expenses	8,021	14,776	3,838	25,868
Profit (loss) from continuing operations before tax	-22,686	-52,533	-95,344	-112,368
Total tax expense (income)	207	134	306	199
Profit (loss) from continuing operations	-22,893	-52,667	-95,650	-112,567
Profit (loss)	-22,893	-52,667	-95,650	-112,567
Total comprehensive income	-22,893	-52,667	-95,650	-112,567
Basic earnings per share				
Total basic earnings per share	-0.21	-0.48	-0.87	-1.03

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2017/01/01To2017/06/30	2016/01/01To2016/06/30
Statements of Cash Flows		
Cash flows from (used in) operating activities, indirect method		
Profit (loss) from continuing operations before tax	-95,344	-112,368
Profit (loss) before tax	-95,344	-112,368
Depreciation expense	28,377	19,329
Amortization expense	488	447
Provision (reversal of provision) for bad debt expense	68	0
Interest income	-2,607	-4,753
Share-based payments	10,106	5,040
Loss (gain) on disposal of property, plan and equipment	-99	0
Impairment loss on non-financial assets	431	55
Other adjustments to reconcile profit (loss)	0	0
Total adjustments to reconcile profit (loss)	36,764	20,118
Decrease (increase) in notes receivable	0	71
Decrease (increase) in accounts receivable	-7,976	9,338
Decrease (increase) in accounts receivable due from related parties	10,435	0
Decrease (increase) in other receivable	-847	-186
Decrease (increase) in inventories	-9,404	-31,650
Decrease (increase) in prepayments	-3,367	-23,891
Decrease (increase) in other current assets	108	-1,256
Total changes in operating assets	-11,051	-47,574
Increase (decrease) in accounts payable	1,518	26,630
Increase (decrease) in accounts payable to related parties	0	-40
Increase (decrease) in other payable	-5,117	-3,082
Increase (decrease) in other payable to related parties	-6	0
Increase (decrease) in other current liabilities	8,163	2,534
Increase (decrease) in net defined benefit liability	-30	-23
Total changes in operating liabilities	4,528	26,019
Total changes in operating assets and liabilities	-6,523	-21,555
Total adjustments	30,241	-1,437
Cash inflow (outflow) generated from operations	-65,103	-113,805
Income taxes refund (paid)	-157	1,652
Net cash flows from (used in) operating activities	-65,260	-112,153
Cash flows from (used in) investing activities		
Acquisition of investments in debt instrument without active market	-83,089	-213,121
Proceeds from disposal of investments in debt instrument without active market	352,935	562,138
Acquisition of financial assets at cost	-67,000	0
Increase in prepayments for investments	0	-20,000
Acquisition of property, plant and equipment	-24,330	-81,774
Proceeds from disposal of property, plant and equipment	114	0
Increase in refundable deposits	-450	0
Decrease in refundable deposits	0	439
Acquisition of intangible assets	-371	-287
Increase in other financial assets	-5,107	-8,708
Decrease in other financial assets	47,683	0
Increase in prepayments for business facilities	-16,014	-35,198
Increase in other prepayments	-7,380	0
Interest received	2,765	5,085
Net cash flows from (used in) investing activities	199,756	208,574
Cash flows from (used in) financing activities		
Exercise of employee share options	1,414	4,332
Net cash flows from (used in) financing activities	1,414	4,332
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase (decrease) in cash and cash equivalents	135,910	100,753
Cash and cash equivalents at beginning of period	309,771	305,619
Cash and cash equivalents at end of period	445,681	406,372
Cash and cash equivalents reported in the statement of financial position	445,681	406,372
Other items qualifying for cash and cash equivalents under the definition of IAS 7	0	0

2017/06/30 Statement of Stockholders' Equity

Accounting Title	Unit: NIS thousand													Total other equity interest	Treasury shares	Total equity		
	Ordinary share	Advance receipts for share capital	Total share capital	Capital surplus	Inappropriated retained earnings (accumulated deficit)	Total retained earnings	Exchange differences on translation of foreign financial statements	Gain (losses) from investments in equity instruments measured at fair value through other comprehensive income	Unrealized gains (losses) on available-for-sale financial assets	Gain (losses) on effective portion of cash flow hedges	Gain (losses) on effective portion of hedges of net investments in foreign operations	Change in fair value of financial liability attributable to change in credit risk of liability	Gain (losses) on remeasurements of defined benefit				Revaluation surplus	Equity related to non-current assets classified as held for sale
Equity at end of period	1,120,005	807	1,120,812	639,611	-356,669	-356,669	0	0	0	0	0	0	0	0	0	0	47,611	1,316,113
Equity at beginning of period after adjustments	1,120,005	807	1,120,812	639,611	-356,669	-356,669	0	0	0	0	0	0	0	0	0	0	47,611	1,316,113
Capital surplus used to offset accumulated deficits	0	0	0	-356,669	356,669	356,669	0	0	0	0	0	0	0	0	0	0	0	0
Profit (loss)	0	0	0	0	-95,650	-95,650	0	0	0	0	0	0	0	0	0	0	0	-95,650
Other comprehensive income	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total comprehensive income	0	0	0	0	-95,650	-95,650	0	0	0	0	0	0	0	0	0	0	0	-95,650
Share-based payments	800	-208	572	13,846	0	0	0	0	0	0	0	0	0	0	0	0	0	13,638
Total increase (decrease) in equity	208	672	-345,821	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-84,112
Equity at end of period	1,120,805	599	1,121,404	293,790	-95,650	-95,650	0	0	0	0	0	0	0	0	0	0	47,611	1,232,029

2016/06/30 Statement of Stockholders' Equity

Accounting Title	Unit: NIS thousand													Total other equity interest	Treasury shares	Total equity		
	Ordinary share	Advance receipts for share capital	Total share capital	Capital surplus	Inappropriated retained earnings (accumulated deficit)	Total retained earnings	Exchange differences on translation of foreign financial statements	Gain (losses) from investments in equity instruments measured at fair value through other comprehensive income	Unrealized gains (losses) on available-for-sale financial assets	Gain (losses) on effective portion of cash flow hedges	Gain (losses) on effective portion of hedges of net investments in foreign operations	Equity related to non-current assets classified as held for sale	Other					
Equity at end of period	1,115,000	2,211	1,118,201	621,319	-197,696	-197,696	0	0	0	0	0	0	0	0	0	0	47,611	1,454,214
Effects of retrospective application and retrospective restatement	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Equity at beginning of period after adjustments	1,115,000	2,211	1,118,201	621,319	-197,696	-197,696	0	0	0	0	0	0	0	0	0	0	47,611	1,454,214
Profit (loss)	0	0	0	0	-112,567	-112,567	0	0	0	0	0	0	0	0	0	0	0	-112,567
Other comprehensive income	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total comprehensive income	0	0	0	0	-112,567	-112,567	0	0	0	0	0	0	0	0	0	0	0	-112,567
Share-based payments	2,190	138	2,328	7,044	0	0	0	0	0	0	0	0	0	0	0	0	0	6,776
Total increase (decrease) in equity	138	2,328	7,044	0	-112,567	-112,567	0	0	0	0	0	0	0	0	0	0	0	-105,199
Equity at end of period	1,118,138	2,349	1,120,487	628,363	-310,263	-310,263	0	0	0	0	0	0	0	0	0	0	47,611	1,281,015